While oncology contributed Rs. 16,100.9 million to remain company's largest therapy area, the key highlight was receipt of 11 new regulatory approvals for medicines and indications
This alliance, covering up to 12 antibody drugs, highlights the growing trend of large-scale collaborations between Chinese biotech firms and global pharmaceutical giants
US federal jury finds Japanese drugmaker liable for anticompetitive agreement delaying generic version of constipation drug Amitiza
Deal includes exclusive option to acquire MiRus’ SIEGEL TAVR system for an additional $3 billion upon milestone achievements
The multi-target collaboration combines Regeneron’s industry-leading antibody capabilities with Parabilis’ novel Helicon peptide platform
Growth driven by strong performance across Sugar Free, RiteBite Max Protein, Everyuth, Glucon-D and Nutralite portfolios
The state has received Rs. 84,000 crore investments in the sector over two years, positioning Hyderabad among the world’s leading life sciences clusters
The acquisition positions Roche more aggressively in digital pathology and precision diagnostics capabilities
The acquisition gives Bayer full rights to PER-001, an experimental therapy now in Phase II clinical trials for Glaucoma and Diabetic Retinopathy
At the center of the deal is TERN-701, a drug recently granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration for adults with Philadelphia chromosome-positive chronic myeloid leukemia
Subscribe To Our Newsletter & Stay Updated
